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Abstract
Background: Inflammatory bowel disease can develop in the context of some rheumatic diseases in childhood,
including juvenile idiopathic arthritis (JIA). Inflammatory bowel disease (IBD) is frequently associated with other
immune-mediated diseases; however, systemic onset JIA (sJIA) has not previously been connected to IBD. Treatment of
sJIA has significantly changed in recent years, possibly causing changes in inflammatory patterns. Therefore, data from
the German Center for Pediatric and Adolescent Rheumtology from 2010 until 2015 were analyzed by retrospective
chart review.
Findings: Eighty-two patients with confirmed diagosis of sJIA were found. Of these, three were identified with a
diagnosis of IBD confirmed by colonoscopy (two cases of Crohn’s disease, one case of ulcerative colitis) 0.8 – 4.3 years
after diagnosis. All three were treated with IL-1 antagonists (anakinra in two cases, canakinumab in one case) and were
well controlled for sJIA symptoms at time of diagnosis of IBD
Conclusions: IBD seems to be a rare, but possible complication of sJIA. Treatment with IL-1 antagonists might be a
relevant factor for a switch in the clinical phenotype of the underlying inflammatory process.
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Findings
Systemic-onset juvenile idiopathic arthritis (sJIA) is
an autoinflammatory disease characterized by in-
creased levels of interleukin(IL)-1 and IL-6 [1]. Ana-
kinra and canakinumab are both medications used
successfully in sJIA, aiming to neutralize the effects
of IL-1 [2, 3].
Inflammatory bowel diseases (IBD) are associated
with several immune-mediated diseases, with almost a
quarter of patients showing first symptoms during
childhood or adolescence [4]. While unspecific mild
bowel inflammation has been described in sJIA, IBD
has not been observed as an extrarticular manifest-
ation [5, 6].
We present three pediatric cases with confirmed diag-
nosis of sJIA who developed IBD diagnosed by histology
and coloscopy during treatment with IL-1 antagonists.
Patients and Methods
The database of the German Center for Pediatric and
Adolescent Rheumatology was searched for all sJIA pa-
tients (n = 82) with a confirmed diagnosis of IBD from
2010 until 2015. Four patients were identified; one was
excluded as histology showed only unspecific round-cell
infiltrate. Chart survey was used to extract demographic
data, date of diagnosis of sJIA and IBD, clinical and la-
boratory data and medications.
Case descriptions
Clinical and laboratory data of the cases at time of
diagnosis of sJIA and of IBD are described in Tables 1
and 2, respectively. (Additional file 1: Table S1 and
Additional file 2: Table S2).
Case I is a Caucasian male. He presented at age 14 years
and 10 months with high quotidian fever with associated
diffuse exanthema, splenomegaly, mild pericardial effusion
and polyarthritis. Infectious workup showed elevated IgG
and IgM antibodies against Parvovirus B19. He did not
complain about abdominal symptoms and had a normal
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bowel ultrasound except for splenomegaly. He received
methylprednisolone pulse therapy and indomethacin and
was started on anakinra, with rapid remission within
3 months.
After 11 months on anakinra he developed increasing ab-
dominal pain and diarrhea. Stool cultures were negative.
Colonoscopy showed ileitis and discontinuous inflamma-
tion in the ascending colon. Histology confirmed granu-
lomatous inflammation. With a diagnosis of Crohn’s
disease he was started on azathioprine and prednisolone,
while anakinra was tapered. He presented 3 months later
with fevers and markedly elevated inflammatory parameters
Table 1 Demographics of the patients, clinical and laboratory data at time of diagnosis of sJIA, and time and dose of anti-IL-
1 medication
Patient 1 2 3
Gender m m f
ANA/RF/HLA-B27 neg/neg/neg neg/neg/n.d. neg/neg/neg
Age at diagnosis 14.8 15.8 6.8
ILAR criteria for subtype Fever, typical rash, splenomegaly,
pericardial effusion
Fever, rash, pericardial/pleural
effusion, hepatomegaly
Fever, rash, pleural
effusion, hepatomegaly
splenomegaly
Affected joints Polyarthritis Polyarthritis Elbows, hips, wrists
Leukocyte count 9100/mm3
(4800–10000)
9100/mm3
(4500–12500)
16800/mm3
(4800–10000)
Platelet count 294000/mm3
(150000–450000)
208000/mm3
(154000–386000)
575000/mm3
(150000–450000)
Ferritin 2926 μg/l
(30–400)
32722 ng/ml
(22–322)
297–1197 μg/l
(30–400)
C-reactive protein 7.4 mg/dl
(0.2–1.0)
28.54 mg/dl
(<0.3)
3.36 mg/dl
(0.2–1.0)
Bone marrow biopsy findings Negative MAS -
Start of IL1-treatment, years after diagnosis 0 years 2.2 years 0.3 years
IL-1 agents, initial dose Anakinra
1.3 mg/kg
Canakinumab
1.8 mg/kg
Anakinra
1.1 mg/kg
normal values in parentheses
neg negative, n.d. not done
Table 2 Colonoscopy findings, clinical and laboratory data at time of diagnosis of IBD of the patients
Patient 1 2 3
Time between diagnoses
of sJIA and IBD
0.9 years 4.4 years 4.7 years
Time between start of
Anti-IL1 agent and IBD
0.9 years 2.2 years 4.4 years
Anti-IL1 agents, dosage Anakinra, 1.3 mg/kg Canakinumab, 1.8 mg/kg Anakinra, 0.7 mg/kg
Other medications None Cyclosporin A None
Colonoscopy, macroscopic
findings
Active, ulcerous ileitis and colitis,
consistent with Crohn’s disease
Active colitis from sigmoid to coecum,
consistent with Crohn’s disease
Colitis in colon descendens,
consistent with ulcerative colitis
Colonoscopy, microscopic
findings
Granulomatous inflammation Inflammatory infiltrate Inflammatory infiltrate
Diarrhea Present Present Present
Macroscopic blood in stool Absent Absent Present
Ferritin 138 ng/ml
(9–80)
154 ng/ml
(30–400)
10 ng/ml
(30–400)
CRP 12.1 mg/dl
(< 0.8)
4.67 mg/dl
(0.02–1.0)
0.44 mg/dl
(0.2–1.0)
Calprotectin/stool Not available 877 μg/g
(<50)
1264 μg/g
(<50)
normal values in parentheses
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without diarrhea. After excluding systemic inflammation or
infection, his colonoscopy was repeated and returned a re-
sult of highly active Crohn’s disease. Treatment with inflixi-
mab and methotrexate was started, leading to rapid and
ongoing remission 8 months later.
Case II is a Caucasian male, who presented at age
15 years and 10 months with fevers, arthritis and exan-
thema and developed polyarthritis, pericardial and pleural
effusion within a few weeks. At that time, he had borderline
positive IgM antibodies against Coxsackie virus, Adeno-
virus and Epstein-Barr virus. He was treated with NSAID
and steroids, but developed two episodes of macrophage
activation syndrome, with recurrence on cyclosporin after
the first episode. Three months prior to the second episode,
he was diagnosed with Influenza A. Twenty-three months
after diagnosis he was started on anakinra after methylpred-
nisolone pulses which led to brief improvement. Three
months later he presented with severe signs of systemic
arthritis and elevated inflammatory parameters. Treatment
with tocilizumab showed no improvement, but canakinu-
mab – in addition to cyclosporine and low dose steroids –
led to rapid and lasting remission over the next 2 years.
After 24 months on canakinumab he presented with fa-
tigue, arthralgias without arthritis and elevated C-reactive
protein, with diarrhea and weight loss. Increasing doses of
canakinumab and prednisolone did not lead to improve-
ment. Infectious work-up showed again borderline posi-
tive IgM antibodies against Coxsackie, but negative stool
cultures. Colonoscopy showed active colitis extending
from proximal sigmoid to the cecum with several, partly
confluent ulcerations. The iliocecal valve was gaping, and
the terminal ileum exhibited erythema and punch defects
of the mucosal membrane. Duodenal biopsy showed
edematous and coarse villi, with detachment of epithelium
and mostly neutrophilic inflammatory infiltrate. Even
without granuloma formation, this was interpreted as
Crohn’s disease, supported by positive antibodies against
Saccharomyces cerevisiae (ASCA). Canakinumab was dis-
continued, and he was started on budenoside and inflixi-
mab, which led to rapid remission, ongoing 18 months
after diagnosis of IBD.
Case III is a Caucasian male of mixed German and
Turkish origin. He presented at age 6 years and 10 months
with fevers, arthritis, exanthema, pleural effusion and oli-
goarthritis. An extensive infectious workup showed no re-
sult. He was treated with indomethacin, steroids and
methotrexate. He presented 4 months later with arthritis,
fevers and elevated inflammatory parameters. Treatment
with steroids and etanercept showed no effect after 3
doses, so he was switched to anakinra, leading to prompt
improvement of clinical signs and laboratory parameters.
He entered long lasting remission, but started to de-
velop mild abdominal symptoms after 3 years on ana-
kinra and methotrexate. Methotrexate was discontinued
6 months later, and in the following months he showed
increasing abdominal pain and blood in his stools. Stool
cultures were negative. He received a colonoscopy 4 years
after starting anakinra, which showed severe inflamma-
tion of the colon descendens consistent with ulcerative
colitis, with histology showing edema of the lamina pro-
pria with inflammatory lymphocytic and neutrophilic in-
filtrate, and also focal inflammation in the crypt walls.
He was continued on low dose anakinra (0.5 mg/kg) and
started on mesalazin and azathioprine, with ongoing
mild gastrointestinal complaints on last follow-up.
Discussion
Here we present three patients with confirmed diagnosis
of sJIA who developed signs of IBD on treatment with
anti-IL1 agents, either anakinra or canakinumab. All cases
fulfilled ILAR criteria for sJIA at the time of diagnosis,
and none had any clinical signs of IBD at that time. Al-
though the age range in these patients falls well within the
described spectrum, the majority of patients with sJIA ini-
tially present below the age of 5 years. All patients devel-
oped typical manifestations of Crohn’s disease or
ulcerative colitis, where monoclonal TNFα antibodies or
DMARDS were required to gain disease control (for com-
parison, see Table 3). The one patient receiving low-dose
anakinra in fact continued to have low grade abdominal
symptoms, possibly indicating an ongoing pro-
inflammatory effect of anti-IL1 medication.
Few reports exist of patients with sJIA developing IBD.
Twenty-nine patients with various subtypes of JIA, includ-
ing three with sJIA, have been linked to IBD on treatment
with etanercept, and one on infliximab [7–9]. All three pa-
tients developed Crohn’s disease between 5 and 12 years
after diagnosis of sJIA on treatment with etanercept; all pa-
tients went into clinical remission after discontinuation of
etanercept and treatment of IBD. A recent survey from the
German biologics registry did find IBD in eleven of 3,071
patients with JIA, but none with sJIA [10]. Endoscopic
studies on 27 JIA patients with gastrointestinal symptoms
also found ulcerative colitis in five patients (19%), but none
with sJIA [5]. Phenotypes of rheumatic diseases can evi-
dently change over time, especially in childhood. sJIA
changes from IL-1 driven acute febrile sJIA to IL-17 driven
chronic active sJIA over time [1]. In endoscopic mucosal
samples, IBD similarly exhibits a strong TH1 phenotype in
early lesions and switches to a TH17 phenotype, with
marked increase in IL-17A, and induction of IL-6 and IL-
23; it can occur subsequent to different categories of JIA as
well as spondyloarthropathies [11, 12]. IBD, especially
Crohn’s disease, is considered an NF-κB activation disorder
as part of the spectrum of autoinflammatory diseases,
where cross-overs have frequently been observed – a
change of sJIA into an IBD phenotype therefore seems at
least possible in theory [13]. In fact, a recent study of
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mucosal biopsies in 33 JIA patients with gastrointestinal
symptoms included eight with sJIA, with two patients with
mild eosinophilic infiltration in the colon, and one 4 year
old patient with active gastrointestinal inflammation [6].
All three patients were exposed to IL-1 antagonists when
developing symptoms of IBD. IL-1 is known to be
expressed at high levels in colonic biopsies from patients
with IBD, supporting the hypothesis of a pro-inflammatory
role. Animal models of colitis both in rabbits and rats im-
prove with blockade of IL-1 [14]. However, recent mouse
models show a differentiated role for IL-1α and IL-1β,
where IL-1α, produced mainly by colonic epithelial cells,
acts in an inflammatory fashion [15]. In comparison, IL-1β,
produced mostly by myeloid cells, promotes healing and re-
pair in colonic tissue; IL-1β deficient mice show more se-
vere colitis with failure of repair mechanisms [16].
Anakinra blocks both IL-1α and IL-1β, but in the mouse
model described, experimental specific IL-1α antibodies
were significantly more efficacious in reducing severity of
colitis compared to external IL-1 receptor antagonist (IL-
1RA). Canakinumab by design specifically targets IL1-β,
with no effect on IL-1α. Disturbance of the IL1-1α/β equi-
librium by these medications might possibly create a pro-
inflammatory environment in the colon, leading to IBD in
selected cases. Patients with active IBD have in fact been
shown to have increased levels of IL-1RA [17]. So far, no
clinical trials have been reported for IL-1 antagonists in
IBD, but one case of IBD worsening with anakinra treat-
ment has been described [18]. One patient with sJIA in a
randomized clinical trial for anakinra did also in fact de-
velop Crohn’s disease [19].
Gastrointestinal symptoms in JIA are not uncommon,
with several series describing results from gastrointestinal
investigations [5, 6]. The majority of cases, including those
with sJIA, show mild, nonspecific inflammation, frequently
with a prominent eosinophilic infiltrate, with more severe
inflammation in only a few cases. It is possible that the
three cases presented here represent the extreme end of
this spectrum. However, all three patients had ongoing, se-
vere abdominal manifestations over several months while
sJIA symptoms were well controlled. The three patients
had extensive infectious work-up during diagnosis, which
showed positive IgM antibodies for various pathogens,
whose impact on the disease progression and change in
phenotype is unclear.
This is a case series; therefore, any conclusions about
an underlying pathological mechanism would be prema-
ture. The impact of medications on the development of
IBD is unclear: the interval between IL-1 blocker treat-
ment and IBD manifestations is highly variable, and it is
possible that methotrexate withdrawal in case 3 lead to
uncovering of a previously subclinical IBD. However,
three cases of IBD in a single tertiary center cohort of
82 patients argues against mere coincidence.
In summary, this is the first report of sJIA patients de-
veloping IBD in temporal connection with IL-1 antagon-
ist treatment. It is not clear if these cases are coincident,
represent a change in patterns of inflammation of sJIA
or are a consequence of treatment. Further efforts
should aim at collecting more patients and elucidating
the underlying disease processes.
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Table 3 Similarities to and differences between the presentation of systemic juvenile idiopathic arthritis and inflammatory bowel
disease in children
Juvenile Idiopathic Arthritis Inflammatory Bowel Disease
Onset of the disease Acute onset with high, quotidian fevers, Typically subacute illness with fatigue, anemia,
and weight loss. Occasionally more fulminant
presentation.
Gastrointestinal symptoms Frequently abdominal pain, also nausea and
anorexia
Loose stools and/or bloody diarrhea,
abdominal pain, tenesmus
Muskuloskeletal symptoms Initially, mild oligoarticular arthritis, frequently
severe polyarthritis over the course of the
disease
Nonerosive, asymmetric arthritis, affecting the
large joints, parallel to intestinal involvement
Skin manifestations Initial presentation with evanescent, salmon-
colored, cutaneous eruption
Erythema nodosum, pyoderma gangrenosum
Laboratory abnormalities Anemia, reactive thrombocytosis, markedly
elevated erythrocyte sedimentation rate and
C-reactive protein. Significantly elevated fer-
ritin. Typically negative antinuclear antibodies
and rheumatoid factor.
Anemia, elevated erythrocyte sedimentation
rate and C-reactive protein, depressed albu-
min level, occult blood in the stool, elevated
fecal calprotectin. Ferritin typically low or nor-
mal. Typically negative antinuclear antibodies
and rheumatoid factor.
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